BRCA1 and ovarian cancer: It should be noted that annotating samples as HRD and HRP based on defects in BRCA1/2 genes provided almost identical separation in progression-free survival for the 25 PARPi-treated ovarian cancers to that yielded by HRProfiler (Supplementary Fig. S12A).